Renaud, S, de Lorgeril, M, Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339 (1992), 1523–1526.
Balkau, B, Eschwege, F, Eschwege, E, Ischemic heart disease and alcohol-related causes of death: a view of the French paradox. Ann Epidemiol 7 (1997), 490–497.
Balkau, B, Eschwege, E, Forhan, A, Slama, G, The French paradox and diabetic patients. Diabetes Care 20 (1997), 1798–1799.
Scheen, AJ, Charbonnel, B, Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
Scheen, AJ, Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Zelniker, TA, Wiviott, SD, Raz, I, Im, K, Goodrich, EL, Bonaca, MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
Bonnet, F, Scheen, AJ, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Scheen, AJ, GLP-1 receptor agonists and cardiovascular protection. Class effect or not?. Diabetes Metab 44 (2018), 193–196.
Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
Ueda, P, Svanstrom, H, Melbye, M, Eliasson, B, Svensson, AM, Franzen, S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, 363, 2018, k4365.
Bauduceau, B, Bordier, L, Bordier, L, Bringer, J, Chabrier, G, Charbonnel, B, et al. Prise de position de la SFD : évaluation du rapport bénéfices–risques des inhibiteurs de SGLT2. Med Mal Metab 13 (2019), 195–209.
Davies, MJ, D'Alessio, DA, Fradkin, J, Kernan, WN, Mathieu, C, Mingrone, G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 (2018), 2461–2498.
Cosentino, F, Ceriello, A, Baeres, FMM, Fioretto, P, Garber, A, Stough, WG, et al. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J, 2018, 10.1093/eurheartj/ehy677 [Epub ahead of print].
Garber, AJ, Abrahamson, MJ, Barzilay, JI, Blonde, L, Bloomgarden, ZT, Bush, MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocr Pract 25 (2019), 69–100.
Arnett, DK, Blumenthal, RS, Albert, MA, Buroker, AB, Goldberger, ZD, Hahn, EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2019, 10.1016/j.jacc.2019.03.009 [pii: S0735-1097(19)33876-8. Epub ahead of print].
Kosiborod, M, Cavender, MA, Fu, AZ, Wilding, JP, Khunti, K, Holl, RW, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
Kosiborod, M, Lam, CSP, Kohsaka, S, Kim, DJ, Karasik, A, Shaw, J, et al. Lower cardiovascular risk associated with SGLT-2i in > 400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol 71 (2018), 2628–2639.
Birkeland, KI, Jorgensen, ME, Carstensen, B, Persson, F, Gulseth, HL, Thuresson, M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
Persson, F, Nystrom, T, Jorgensen, ME, Carstensen, B, Gulseth, HL, Thuresson, M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetes patients (CVD-REAL Nordic) when compared to DPP-4 inhibitors: a multinational observational study. Diabetes Obes Metab 20 (2018), 344–351.
Scheen, AJ, An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 18 (2019), 295–311, 10.1080/14740338.2019.1602116 [Epub ahead of print].
Yang, JY, Wang, T, Pate, V, Gower, EW, Crowley, MJ, Buse, JB, et al. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. Diabetes Obes Metab 21 (2019), 1223–1236, 10.1111/dom.13647 [Epub ahead of print].
Neal, B, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Erondu, N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
